Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Black Skin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Black Skin. Displaying page 1 of 1.
    EudraCT Number: 2015-003972-64 Sponsor Protocol Number: 2015-09 Start Date*: 2019-07-02
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE
    Full Title: Plasma and tissue pharmacokinetics of amikacin administrated by dressing impregnated in burns patients
    Medical condition: burns patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005651-17 Sponsor Protocol Number: plexusogsirkulasjon Start Date*: 2013-06-13
    Sponsor Name:Oslo Universitetssykehus
    Full Title: Plexus brachialis block and circulation. Comparing effects on skin microcirculation and macro circulation of lidocain brachial plexus block with versus without epinephrine.
    Medical condition: human microcirculation and haemodynamic changes (macrosirculation) in healthy volunteers.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001218-24 Sponsor Protocol Number: TDL-CS-001 Start Date*: 2014-06-05
    Sponsor Name:Trichocare Diagnostics Ltd
    Full Title: An open label, intra-subject, controlled multi-centre study to assess the concordance (specificity and sensitivity) between Colourstart® Test 73 mcg Cutaneous Patch and Finn Chamber in the detectio...
    Medical condition: Para-Phenylenediamine allergy
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004848 10065649 PPD skin test positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002833-19 Sponsor Protocol Number: SPD488-402 Start Date*: 2006-10-12
    Sponsor Name:Shire Pharmaceutical Development
    Full Title: A randomised, multi-centre, open-label study to evaluate the efficacy of VANIQA with laser treatment versus laser treatment alone in female subjects with excessive facial hair (facial hirsutism)
    Medical condition: Excessive facial hair in females (Facial hirsutism)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020112 Hirsutism LLT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005532-18 Sponsor Protocol Number: PLX-CLI-03 Start Date*: 2017-01-02
    Sponsor Name:Pluristem Ltd.
    Full Title: A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-Group Phase III Study to Evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX-PAD for the Treatmen...
    Medical condition: Critical Limb Ischemia (CLI)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10058069 Critical limb ischemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Prematurely Ended) AT (Completed) HU (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002195-12 Sponsor Protocol Number: BNT111-01 Start Date*: 2021-04-27
    Sponsor Name:BioNTech SE
    Full Title: An open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD1-/ PD-L1-refractory/relapsed, unresectable Stage III or IV melanoma
    Medical condition: Anti-PD1-/ PD-L1-refractory/relapsed, unresectable Stage III or IV melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072449 Desmoplastic melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024220 Lentigo maligna recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024218 Lentigo maligna PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024223 Lentigo maligna stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024224 Lentigo maligna stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066600 Melanoma recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079054 Naevoid melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029488 Nodular melanoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042551 Superficial spreading melanoma stage III PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042552 Superficial spreading melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042553 Superficial spreading melanoma stage unspecified PT
    20.0 100000004858 10027156 Skin melanomas (excl ocular) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000381-20 Sponsor Protocol Number: 27820 Start Date*: 2007-11-16
    Sponsor Name:Merck Serono S.A. - Geneva
    Full Title: A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple...
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) FR (Completed) GB (Completed) CZ (Completed) BE (Completed) EE (Completed) AT (Completed) PT (Completed) NL (Completed) DE (Completed) DK (Completed) IT (Completed) GR (Completed) LV (Completed) LT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-003415-22 Sponsor Protocol Number: AP-W-CLI-2018-8 Start Date*: 2019-03-22
    Sponsor Name:Aurealis Oy
    Full Title: A Phase 1/2A clinical study to evaluate the safety, tolerability and efficacy of single and repeated doses of AUP1602-C as topical treatment of diabetic foot ulcers
    Medical condition: Diabetic foot ulcers
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021015-16 Sponsor Protocol Number: TFM-CL3-002 Start Date*: 2010-09-30
    Sponsor Name:Olympus France SAS
    Full Title: A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment with Trafermin 0.01% Spray in Patients with Diabetic Foot Ulcer of Neuropathic ...
    Medical condition: Wound closure rate of diabetic foot ulcers (DFUs) of neuropathic origin.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) BE (Completed) DK (Completed) SE (Completed) DE (Completed) NL (Completed) HU (Completed) SK (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021014-33 Sponsor Protocol Number: TFM-CL3-001 Start Date*: 2010-09-30
    Sponsor Name:Olympus France SAS
    Full Title: A Phase III, Double-Blind, Placebo Controlled, Parallel Group, International, Multicenter Study of 12 Weeks Treatment with Trafermin 0.01% Spray in Patients with Diabetic Foot Ulcer of Neuropathic ...
    Medical condition: Wound closure rate of diabetic foot ulcers (DFUs) of neuropathic origin.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012664 Diabetic foot ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003867-76 Sponsor Protocol Number: RRK4249 Start Date*: 2013-11-07
    Sponsor Name:University Hospitals Birmingham NHS Foundation Trust
    Full Title: A prospective, randomised controlled trial to determine the safety and efficacy of steroid impregnated tape compared to standard therapy with silver nitrate in the treatment of over-granulating per...
    Medical condition: Over-granulation of peritoneal dialysis exit site in patients with End Stage Renal Failure
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10034660 Peritoneal dialysis PT
    18.0 10042613 - Surgical and medical procedures 10008831 Chronic ambulatory peritoneal dialysis LLT
    18.0 10042613 - Surgical and medical procedures 10067974 Automated peritoneal dialysis LLT
    18.0 10022117 - Injury, poisoning and procedural complications 10067594 Peritoneal dialysis complication PT
    18.0 10042613 - Surgical and medical procedures 10064116 Continuous ambulatory peritoneal dialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002126-64 Sponsor Protocol Number: CA184-004 Start Date*: 2006-05-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Exploratory Study to Determine Potential Predictive Markers of Response and/or Toxicity in Patients with Unresectable Stage III or IV Malignant Melanoma Randomized and Treated with Ipilimumab (M...
    Medical condition: Melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004842-92 Sponsor Protocol Number: SECOMBIT Start Date*: 2016-06-30
    Sponsor Name:FONDAZIONE MELANOMA ONLUS
    Full Title: A three arms prospective, randomized phase II study to evaluate the best sequential approach with combo immunotherapy (ipilimumab/nivolumab) and combo target therapy (LGX818/MEK162) in patients wit...
    Medical condition: Metastatic melanoma and BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Ongoing) DE (Completed) GR (Completed) AT (Ongoing) GB (GB - no longer in EU/EEA) SE (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010777-20 Sponsor Protocol Number: 155-CL-031 Start Date*: 2009-12-15
    Sponsor Name:Astellas Pharma Global Development, Inc. (APGD)
    Full Title: A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin’s Lymphoma Who Are Ineligible For Or Have Previously Received ...
    Medical condition: CD20-positive primary or transformed diffuse large B cell lymphoma (DLBCL), grade 3 follicular lymphoma (FL) and mantle cell lymphoma (MCL).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029592 Non-Hodgkin's lymphomas NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:20:47 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA